Insights from 2023 ESMO Annual Meeting
ESMO 2023 Insights: "Omission of Breast Surgery After Neoadjuvant Systemic Therapy for Invasive Cancer - 3-Year Preplanned Primary-Endpoint on a Phase 2 Multicentre Prospective Trial"
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Henry Kuerer
By
Insights from 2023 ESMO Annual Meeting
FEATURING
Henry Kuerer
Login to view comments.
Click here to Login
Breast